Brought to you by 
Biotie issues €85.4mm in stock to acquire Synosia
17 Aug 2021
Executive Summary
Finnish biotech Biotie Therapies Corp. has agreed to acquire all the outstanding stock and warrants of private spec CNS pharma Synosia Therapeutics Inc. Biotie will issue 161.4mm of its shares, valued at €85.4mm ($109.8mm), as payment. Another 14.9mm Biotie shares are being put in a treasury to be used when future Synosia options are exercised. Post acquisition, Synosia stockholders will own 50% of Biotie.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biotie issues €85.4mm in stock to acquire Synosia
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice